Skip to main content

Table 1 Patient’s characteristics according to the presence or absence of Metabolic Syndrome

From: Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study

 

Overall

No MetS

MetS

p

Patients (%)

349

262/349 (75 %)

87/349 (25 %)

 

Age, years

64.5 ± 6.09 (66;61/69)

64.05 ± 6.53 (65;59/69)

64.92 ± 4.87 (65;62/68)

0.473

BMI, kg/m2

27.4 ± 12.77 (26.12;24/29)

26.56 ± 3.69 (26;24/28.4)

28.64 ± 3.45 (28;26.3/30.57)

<0.001

PSA, ng/ml

9.87 ± 11.84 (7.07;5.08/10)

10.41 ± 12.28 (7.11;5.1/9.8)

10.80 ± 16.75 (8.18;4.39/11.95)

0.687

TRUS Volume, ml

53.07 ± 29.59 (48;35.1/60)

55.43 ± 34 (47.75;36/60)

53.4 ± 24.01 (50;37/67)

0.661

Waist, cm

99.51 ± 9.85 (99;94/106)

98.87 ± 9.45 (98;93/105)

102.77 ± 11.3 (102.5;96/110)

0.009

Glycemia, mg/dl

101.86 ± 23.42 (96;88/108)

98.48 ± 19.15 (94;87/104)

113.19 ± 25.7 (111;97/111)

0.003

Triglyceridemia, mg/dl

131.8 ± 64.4 (115;83.7/161.2)

126.07 ± 58 (110;83/155)

152.11 ± 78.88 (133;87/199.5)

0.040

HDL, mmol/l

51.8 ± 14.06 (50;42/59)

52.87 ± 13.44 (51;43/60)

47.72 ± 15.9 (45;36.5/57)

0.023

Hypertension

182/349 (52 %)

113/262 (43 %)

69/87 (79 %)

<0.001

  1. Data are presented as mean ± SD (median; IQR)